Monoamine oxidase inhibition and brain amine metabolism after oral treatment with toloxatone in the rat.
Rats were administered toloxatone 100 mg kg-1 p.o., and killed 0.5 to 8 hours later. Toloxatone reversibly inhibited type A MAO, but did not affect the activity of type B MAO in whole brain. Cerebral concentrations of noradrenaline, dopamine and 5-hydroxytryptamine were increased after toloxatone, while their metabolite concentrations were reduced. Synaptosomal uptake processes of these amines were not altered by tolaxatone.
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001679:Biogenic Amines / Q000378:metabolism*; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D003641:Deamination; D004298:Dopamine / Q000378:metabolism; D008297:Male; D008996:Monoamine Oxidase Inhibitors; D009638:Norepinephrine / Q000378:metabolism; D010080:Oxazoles / Q000494:pharmacology*; D023303:Oxazolidinones; D010084:Oxidation-Reduction; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D013574:Synaptosomes / Q000378:metabolism; D013997:Time Factors
D000928:Antidepressive Agents; D001679:Biogenic Amines; D008996:Monoamine Oxidase Inhibitors; D010080:Oxazoles; D023303:Oxazolidinones; D012701:Serotonin; C010798:toloxatone; D004298:Dopamine; D009638:Norepinephrine